https://doi.org/10.55788/8df3d5b5
The IL-23p19 inhibitor risankizumab proved to be efficacious and had a good safety profile in randomised clinical trials. However, data on its effectiveness and safety in the real-world daily clinical practice setting is scarce [1]. This was the rationale for assessing the real-world outcome of this agent in a daily clinical practice setting. “Drug survival acts as a proxy marker for treatment effect and safety,” explained Dr Zenas Yiu (University of Manchester, UK) [2]. Only a few small studies reported on the real-world drug survival of brodalumab and risankizumab. Therefore, Dr Yiu and his team conducted a cohort study using the BADBIR, a national pharmacovigilance registry including patients with psoriasis from the UK and the Republic of Ireland, with data collected between November 2007 and June 2023.
The analysis included 19,043 treatment courses from 11,877 participants with a median follow-up time of 2.3 years. The older biologics had larger cohorts, whereas newer treatments had smaller cohorts with shorter follow-up times. Most participants were treated with adalimumab (n=6,815), followed by ustekinumab (n=5,639). A further 832 participants were treated with risankizumab and 1,258 with guselkumab.
Therapy with the IL-23p19 inhibitors had the highest survival time with respect to effectiveness (guselkumab adjusted HR 0.28; 95% CI 0.15–0.53; risankizumab aHR 0.38; 95% CI 0.16–0.87), whereas adalimumab showed a lower survival compared with all other biologics (aHR 1.98; 95% CI 1.76–2.23). Biologics targeting IL-17 had similar drug survival earlier and lower drug survival later in follow-up compared with ustekinumab. Regarding safety, the longest restricted mean survival times were seen with p19 inhibitors and ustekinumab (see Table).
Table: Restricted mean survival time (RMST) at 2 years [2]

Dr Yiu emphasised that the current study included the largest cohort of psoriasis patients on IL-23p19 inhibitors reported thus far. It showed that people with psoriasis persist with IL-23p19 inhibitors for up to an estimated 21 weeks longer for effectiveness and 13 weeks longer for safety compared with other biologics over 2 years on average. “These results may be valuable when discussing treatment choices where the patients value treatment effect longevity,” Dr Yiu concluded.
- Gordon KB, et al. Lancet 2018;392:650–61.
- Yiu Z. Drug survival of interleukin-23 p19 inhibitors compared to other biologics for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). D1T01.1K, EADV Congress 2023, 11–14 October, Berlin, Germany.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis Next Article
High-dose subcutaneous spesolimab prevents GPP flares up to week 48 »
« IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis Next Article
High-dose subcutaneous spesolimab prevents GPP flares up to week 48 »
Table of Contents: EADV 2023
Featured articles
Tapinarof on course to become a new topical treatment in AD
AD and Eczema in 2023
Tapinarof on course to become a new topical treatment in AD
Upadacitinib provides sustained skin clearance in adolescents and adults with AD
Sustained deep clinical and itch responses with novel IL-13 inhibitor
IL-13 inhibitor shows potential in atopic dermatitis
Encouraging results for amlitelimab in atopic dermatitis
Chronic hand eczema: patients share similar molecular signatures regardless of AD status
Severe hand eczema: dupilumab could be a future treatment
Psoriasis News
Dual IL-17 blockade yields efficacy on joints and skin
High-dose subcutaneous spesolimab prevents GPP flares up to week 48
Drug survival of guselkumab and risankizumab seems superior to other biologics
IL-23 blockers may lower the risk of developing inflammatory and psoriatic arthritis
First-in-class oral IL-23 inhibitor safe and effective for moderate-to-severe plaque psoriasis
Hidradenitis Suppurativa: End of the Diagnostic and Therapeutic Draught
Skin tape stripping allows a novel precision medicine approach in HS
Nanobodies: A novel way to treat HS
Anti-IL17 blockade leads to maintained pain reduction in patients with HS
Vitiligo: Novel Treatment Options
JAK1 inhibition: a promising forthcoming treatment option in vitiligo
Vitiligo: Continuation of topical ruxolitinib successful in many initial non-responders
Alopecia Areata: Novel Developments
JAK3/TEC inhibition achieves clinically meaningful responses in AA
Alopecia areata: remarkable regrowth rates with deuruxolitinib
Botanical drug solution improves hair regrowth in children and adolescents with AA
What’s New in Other Disease Entities
Nemolizumab shows high success rates in prurigo nodularis
Remibrutinib reduces itch, sleep problems, and activity impairment in patients with CSU
Innovative wound gel reduces frequency of painful dressing changes in epidermolysis bullosa
Best of the Posters
Women with psoriasis face increased adverse effects with systemic therapy
Improved AI tool shows high sensitivity rates in skin cancer detection
Dermoscopy training combined with AI significantly improves skin cancer detection
Related Articles
August 12, 2021
Long-term results from ground-breaking melanoma trials
November 28, 2023
Improved AI tool shows high sensitivity rates in skin cancer detection

August 28, 2020
Adjuvant pembrolizumab: durable RFS for stage III melanoma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com